Payment overview · 2025
General Payments
$174.03
10 reported records · 5 companies
Healthcare provider profile · identity verified
Daniel J Garlow, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CONCORDIA, KS · NPI 1730470097
Verified facts
What the public records show
CMS Open Payments records show Daniel J Garlow, M.D. received $174.03 in general payments during 2025 across 10 reported records.
PFIZER INC. accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $95.09 | 54.6% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.23 | 18.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.81 | 9.7% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $15.19 | 8.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.71 | 8.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $174.03 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $95.09 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $81.02 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
227 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 501 | 77 |
| Losartan Potassium | Losartan Potassium | 391 | 75 |
| Omeprazole | Omeprazole | 347 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 58 |
| Gabapentin | Gabapentin | 299 | 55 |
| Potassium Chloride | Potassium Chloride | 298 | 48 |
| Lisinopril | Lisinopril | 267 | 50 |
| Furosemide | Furosemide | 262 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 254 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 228 | 35 |
| Eliquis | Apixaban | 227 | 28 |
| Celecoxib | Celecoxib | 213 | 47 |
| Pregabalin | Pregabalin | 208 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 197 | 36 |
| Tramadol Hcl | Tramadol Hcl | 174 | 43 |
| Trazodone Hcl | Trazodone Hcl | 173 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 37 |
| Metformin Hcl Er | Metformin Hcl | 154 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 147 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 146 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 29 |
| Ezetimibe | Ezetimibe | 128 | 15 |
| Simvastatin | Simvastatin | 121 | 19 |
| Carvedilol | Carvedilol | 120 | 21 |
| Prednisone | Prednisone | 118 | 87 |
| Clopidogrel | Clopidogrel Bisulfate | 113 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 113 | 47 |
| Metformin Hcl | Metformin Hcl | 110 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 107 | 12 |
| Atenolol | Atenolol | 106 | 18 |
| Spironolactone | Spironolactone | 106 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 102 | 16 |
| Cephalexin | Cephalexin | 101 | 52 |
| Mirtazapine | Mirtazapine | 99 | 15 |
| Myrbetriq | Mirabegron | 98 | 11 |
| Ozempic | Semaglutide | 95 | 17 |
| Allopurinol | Allopurinol | 93 | 20 |
| Famotidine | Famotidine | 92 | 15 |
| Farxiga | Dapagliflozin Propanediol | 92 | 13 |
| Donepezil Hcl | Donepezil Hcl | 86 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 23 |
| Buspirone Hcl | Buspirone Hcl | 83 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 82 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 11 |
| Clonazepam | Clonazepam | 76 | 16 |
| Memantine Hcl | Memantine Hcl | 75 | suppressed |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Lorazepam | Lorazepam | 61 | 15 |
| Alendronate Sodium | Alendronate Sodium | 58 | suppressed |
| Bupropion Xl | Bupropion Hcl | 58 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 58 | 50 |
| Meloxicam | Meloxicam | 56 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 12 |
| Montelukast Sodium | Montelukast Sodium | 54 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 52 | suppressed |
| Glipizide Er | Glipizide | 51 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | suppressed |
| Entresto | Sacubitril/Valsartan | 47 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | 12 |
| Fentanyl | Fentanyl | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Alprazolam | Alprazolam | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | 13 |
| Invokana | Canagliflozin | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Estradiol | Estradiol | 37 | suppressed |
| Nystatin | Nystatin | 35 | 16 |
| Ondansetron Odt | Ondansetron | 35 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 19 |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 24 |
| Jardiance | Empagliflozin | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 18 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 13 |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 14 |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Probenecid-Colchicine | Probenecid/Colchicine | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $174.03 · 10 records | PFIZER INC. | ABRYSVO, COMIRNATY, DALVANCE, EVENITY, LEQVIO, PREVNAR 20, SKYCLARYS | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error